The future of genomics in pathology by Wall, Dennis Paul Paul & Tonellato, Peter J
 
The future of genomics in pathology
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Wall, Dennis P., and Peter J. Tonellato. 2012. The future of
genomics in pathology. F1000 Medicine Reports 4.
Published Version doi:10.3410/M4-14
Accessed February 19, 2015 10:47:56 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436267
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAThe future of genomics in pathology
Dennis P. Wall
1,2* and Peter J. Tonellato
1,2
Addresses:
1Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215;
2Center for Biomedical
Informatics, Harvard Medical School, Boston, MA
*Corresponding author: Dennis P. Wall (dpwall@hms.harvard.edu)
F1000 Medicine Reports 2012, 4:14 (doi:10.3410/M4-14)
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. You may not use this work for commercial purposes.
The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/m/4/14
Abstract
The recent advances in technology and the promise of cheap and fast whole genomic data offer the
possibility to revolutionise the discipline of pathology. This should allow pathologists in the near
future to diagnose disease rapidly and early to change its course, and to tailor treatment programs to
the individual. This review outlines some of these technical advances and the changes needed to make
this revolution a reality.
Introduction
Pathology is the branch of medicine that diagnoses the
nature of much human disease and forms the basis for
treatment. It is the division of the hospital where your
bloodsamples,cultures,Papsmears,andbiopsiesaresent.
Pathologists are experts at interpreting microscopic views
of body tissues, and are the responsible authority on
making diagnoses that lead to disease treatment and
prevention. When your doctor tells you that you have
elevated cholesterol and prescribes exercise and Lipitor,
he or she is acting on the results of a test report from a
pathologist. And, when your doctor tells you they are
waiting for the test results, he or she is really waiting for a
pathologist to provide a definitive interpretation and
clinical description of one or more diagnostic tests and
data conducted on the blood or other tissue you provided
earlier. In short, pathology provides the fundamental lab
tests, data and clinical interpretation (to the tune of
7.1 billion laboratory tests in 2009) that form the core of
a patient’s medical record and the data that drives
healthcare.
While the field of pathology dates back to the Greek
physician Hippocrates, pathology’s impact on health has
relied heavily on a steady stream of technological
advances. The invention and enhancement of the light
microscope [1] enabled the rapid evolution in our
understanding of infectious diseases and concomitantly
launched the field of modern pathology through the
efforts of Rudolph Virchow [2]. The invention of the
electron microscope in the 20th century enabled major
advances in our ability to differentiate states and stages of
diseases. The invention of nucleic acid-based diagnostics
represented another key innovation for the field of
pathology, and paved the way to more complex multiplex
testing with dozens of tests possible from a single blood
sample. In a similar way, digital imaging, facilitated
by advancements in both emission energy detection
and computer technology, likewise has generated a new
platform for pathology to conduct high-resolution
diagnostic testing, and thereby provides more detailed
quantification of the diagnoses used in the clinical
discrimination of disease and corresponding insight and
guidance into more individualized disease treatments.
Nevertheless, the rate of uptake of new technologies by
the field of pathology has been slow. The punctuated
jumps forward in our understanding of infectious disease
and ability to conduct diagnostics with the compound
microscope came nearly 150 years after its invention.
Today, nearly 80 years after the invention of the electron
microscope, disagreement remains about its full value in
diagnostic practice. Digital imaging took nearly ten years
to penetrate into standard practices of medical pathology,
despite being established in virtually all other branches
of the hospital, and polymerase chain reaction (PCR)
Page 1 of 5
(page number not for citation purposes)
Published: 02 July 2012
© 2012 Faculty of 1000 Ltdtechnologies took approximately 5 years to take hold,
again despite widespread adoption in medical research.
In all cases, by the time these critical tools percolated into
the standard practice of hospital pathology they were
no longer new, but well established, and in some cases
already being replaced by alternative strategies and
competing technologies.
There is no doubt that the stereotype of the pathologist
wearing tweed, studying slides under a microscope
alongside a dead body persists in part because of this
seeming reluctance to adopt new technologies. At the
sametime,thereisnodoubtthatpathologyhasremained,
and likely will remain, the backbone of the quantification
and laboratory testing used throughout healthcare.
Regardless of the historical delays to assimilate new
technologies into pathology best practice and in spite of
the typical barriers to any new technology adoption, a
“game-changing” technological innovation has emerged
that the field of pathology cannot afford to ignore.
The innovation is next generation sequencing. Unlike
other inventions that have sharpened the clinical impact
of pathology, genomic sequencing technologies are
undergoing regular upheavals at unprecedented speeds.
Parallel developments in ligation-based methods, pyro-
sequencing, polony-based approaches, and single-
molecule sequencing have created a fiercely competitive
marketplace that is challenging historical leaders in the
field, including array-centric companies, while simulta-
neously bankrupting early pioneers of newer techniques.
In this competitive landscape, quality and speed are both
rocketing upward. The fastest technologies can sequence
an entire human genome, 3 billion bases, in hours, and
corresponding costs have dropped from $30,000 to
$4,000 within about a year. And while there remains
some variation in quality, speed, and cost, that variation
is quickly evaporating through market demand. The
thousand dollar genome will soon arrive [3].
Genomic pathology
The field of pathology cannot afford to ignore the next
generation sequencing innovation because, in the hands
of medical pathologists, it has the potential to reshape the
fabric of healthcare and make personalized medicine a
ubiquitous reality. Another reason is that unlike all others
thathaveadvancedtheimpactofpathologyonhealthcare,
thepracticeofnextgenerationwholegenomeanalysiscan,
should, and will replace many current standard pathology
practices of diagnosis and prognosis on which proper
therapyanddiseasemanagementrelytoday,thesamebest
practice standards of pathology that drive considerable
proportions of the clinical decision-making process [4,5].
Pathologists are the direct link between analysis and
interpretation of medical data and care delivery: they
order, conduct, and interpret the results of hundreds of
localized tests to arrive at the medical conclusions that
enable proper care. A large percentage of these tests are
commoditized molecular diagnostics, outsourced to the
appropriate provider. While every test represents an
innovation in healthcare, it is the pathologist’s interpreta-
tion of the test results that actually leads to improvements
in health, and next generation sequencing data is no
different.Justlikestandard molecular diagnostics,one can
order the genome and/or transcriptome for the patient,
but it is the proper clinical interpretation that will add
the value for healthcare. It is difficult to imagine next
generation genomics having any tangible impact on
health if fractionated throughout multiple branches of
the hospital. However, for pathology to succeed at
translating this innovation into actionable health infor-
mation, pathology departments must shed their stodgy
stereotype and rise to the challenge of not only reacting in
an appropriate timeframe to the innovation of next
generation genomics and all that comes with it but also
addressing and resolving the challenges presented by key
barriers to entry.
Whole genomic data should become a vital component
of the healthcare enterprise, and when one considers the
historical role pathology has played in this enterprise, it
is clear that pathology is the most logical home for whole
genome analysis-based clinical decision support.
Personalized care through genomic pathology:
steps and barriers
We have begun to establish a national agenda for the
future of pathology in personalized medicine [6], high-
lighting key areas that must be addressed in order for
pathology to play a leading role in the clinical application
of whole genome analysis. These are (1) defining clinical
actionability,(2)designingaclinicalinterpretationsystem
to generate medical impact reports from next genera-
tion sequencing data and whole genome analysis, and
(3) training a new breed of genomic pathologist through
novel, national education programs.
Defining clinical actionability
Guidelines and recommendations have been developed
[7-9] that will help guide the process of developing a
nationally agreed upon set of criteria that must be met in
order for whole genomic analysis to penetrate effectively
into the clinic. These recommendations and guidelines
need re-evaluation within the context of recent techno-
logical advances. Taking a step forward, we propose that
the definition of clinical actionability should be focused
on genomic analysis, which qualifies for medical
insurance cover in countries like the USA and is provided
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them. Such analysis is geared towards specific clinical
outcomes minimally including treatment and prognosis
risk assessment. With this functional definition, a variant
is clinically actionable if, for example, the variant is used
to determine whether a patient with cancer will respond
to erlotinib, sunitinib, neither, and, if neither, whether a
clinical trial is underway and enrolling new candidates
with that variant for experimental treatment. Proof of
concept exists that an individual’s genome can inform
care [10], and additional evidence is mounting, but now
is the time to settle on the minimum criteria for clinically
actionable genomic variants. While whole genome
analysis will, at least for some period of time, generate
ancillary findings, the field of pathology has a rich history
of handling ancillary data within clinical contexts. The
autoanalyzer technology developed by Skeggs in the
1950s was yet another key innovation that enabled a leap
forward in pathology-driven precision medicine [11],
enabling dozens of tests to be conducted simultaneously
with high accuracy and speed. However, while all tests
were done simultaneously, not all were relevant to the
clinical context under study. These ancillary findings are
of the same nature, though of smaller dimensionality, as
whole genome analysis data. In this context, pathology is
positioned to play the key role in the implementation of
whole genome analysis as a clinical test, with the
understanding that genomic testing is fundamentally no
different from other types of laboratory testing. We take
the stance that “clinical grade genomics” and “clinically
actionable variation” must fall under the same type of
regulatory oversight as other clinical testing and therefore
that the College of American Pathologists and other
international/national pathology organizations should
seize the initiative and develop global/international
standards and regulations governing genome testing.
Having such regulation in place will ensure repeatability
and measurable quality, but will also facilitate the
dialogue between medical insurance and government
agencies on the one hand and medical practices on the
other and enable faster resolution of reimbursement
funding questions.
Building a clinical variant interpretation system
Virtually every aspect of whole genome analysis can be
commoditized and reliably outsourced, save clinical
grade interpretation. This last step is the most crucial
and involves a novel close coupling between clinicians
and biomedical informatics specialists. Proper clinical
interpretation requires integration of numerous layers of
information that pathologists are trained in, but the
analysis of whole genomics data adds a volume of scale
and complexity that requires a new kind of sophistica-
tion and knowledge. Scaling up from standard molecular
diagnosticstogenomics inthe pathology lab is contingent
on having an interpretation system in place that enables
rapid assessment within a clinical time window.
The natural starting point will be to determine and validate
how, when and where whole genome analysis can replace
the standard set of molecular diagnostic tests being
conducted today. Based on an analysis of the Association
for Molecular Pathology’s solid tumor test directory [12],
over 600 tests are in use for analysis and clinical inter-
pretation of solid tumors for more than 90 conditions. By
mapping these into a network of test types (e.g. mutational
analysis or amplification-based test) and cancer types, we
calculate that 85% will be immediately replaceable with
whole genome analysis for multiplex clinical annotation
and medical impact assessment (Figure 1).
Pathology, by enlisting new professionals in genomic
medicine, needs to gain control of the effort to establish a
certified, clinical grade variant database. Current sequence
variant databases have been built through an ad hoc
process designed to support research activities. They fall
short of what is needed for delivery of accurate, safe and
effective patient care. Clinical laboratory testing using
human genome sequence data requires the creation,
ongoing support, and national regulatory oversight of a
clinical grade database. With this in place, we will be able
to establish standard best practices quickly and propagate
newgenomicdiscoveriesnationwidewithasimpleclickof
a button. These discoveries can then be integrated with
other critical pieces of medical record data to inform
decisions within a clinical timeframe. Such data should
include standard histopathology, but should also soon
include prediction data from digital slide scanning and
image analysis technologies, a field that is developing at
a rapid pace and that too holds tremendous potential
for rapid, fine grained and clinically accurate disease
characterization [13].
Training the future “genomic medicine” pathologists
We have to train our future doctors to understand the
whole genomics analysis pipeline and to be able to
interpret medical impact reports that contain genomically
informeddiagnoses.Pathologyprogramshavetoembrace
the innovation of next generation genomics by establish-
ing residency training programs that provide all the skills
necessarytointerpretandactonwholegenomicdata.This
is already happening now [14]. In the US, a national
committee has been formed, including members of the
Pathology Program Directors (PRODS) and other key
stakeholders, to disseminate model curricula and support
their widespread implementation. We are moving fast
toward definitions of the core competencies in genomics
and personalized medicine, and it is likely that, within
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demonstrate proficiency in these areas.
Conclusions
The promise of whole genomic data is within reach. We
will be able to diagnose rapidly and early to change the
course of disease, to prevent adverse drug combinations
and promote beneficial ones, to prevent inappropriate
dosing, and to tailor treatment programs to the indivi-
dual. This will dramatically improve health while staving
off massive failures in the pharmaceutical industry
such as rofecoxib and celecoxib [15]. However, this
transformation of “personalized genomics” from party
hype into clinical action requires disruptive computa-
tionalinnovation at the heartofthe healthcare enterprise.
This is pathology’s time to seize the opportunity in pace
and be in tune with the technological innovations of
modern human genomics. Getting there will require a
national revamp of hospital pathology to ensure that
modern genomic practices are deeply integrated with and
regulated by the same standards as any other clinical test
in patient care. In short, we must embed high-powered
computational analysis and clinical assessment of human
genomes directly into the pipeline of standard care testing
Figure 1
A network view of a sample of tests and diseases found in the Association for Molecular Pathology’s solid tumor test directory [12]. A total of 45 nodes
and 96 edges are depicted in the figure. The nodes are the most common tests and diseases in the directory and edges are drawn from tests to disease if the
test is used commonly for disease characterization. The extent of genetic testing suggests that next generation sequencing and whole genomic analysis
approaches have the potential to replace 85% of the tests found in this directory, greatly simplifying the network and having the potential to streamline
the industry.
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the “thousand dollar genome” achieves its potential to
make personalized medicine a widespread reality.
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